Anaveon is developing IL-2 complexes, specifically ANV419 and ANV600, which enhance effector T cell functions to improve immune responses in cancer treatment. The company addresses the need for safe and effective immunotherapies for patients with high unmet medical needs by utilizing protein engineering to optimize cytokine activity.
Funding
$155.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FCFounders
Product
Problem
Many cancer patients do not respond to existing immunotherapies, highlighting a need for safer and more effective treatments that can harness the power of the immune system to fight cancer. Current immunotherapies may also have limitations in modulating the immune response for autoimmune diseases and transplantation.
Solution
Anaveon is a biopharmaceutical company developing cytokine-based therapies, including IL-2 complexes and proximity-activated cytokines (PACs), designed to enhance and modulate immune responses for the treatment of cancer, autoimmune disorders, and transplantation. The company utilizes protein engineering to create novel treatments that are both safe and effective. Their lead compounds, such as ANV419 and ANV600, are designed to improve effector T cell function and amplify tumor-specific T cells within the tumor microenvironment. Anaveon's approach extends beyond cancer to address immune tolerance and inflammatory diseases, leveraging cutting-edge protein engineering to develop antibodies that selectively deplete pathogenic T cells.
Target Audience
The primary target audience includes patients with cancer and autoimmune diseases, as well as those undergoing transplantation, and healthcare professionals seeking innovative immunotherapies.
Features
- ANV419: An IL-2/anti-IL-2 antibody fusion protein designed to enhance CD8+ T cell function. Currently in Phase I/II clinical trials.
- ANV600: A bispecific molecule designed to amplify tumor-specific T cells within the tumor microenvironment. IND approval for Phase I/II clinical study.
- Proximity-activated cytokines (PACs): Novel cytokine approach for immunomodulation and tolerance.
- Antibody development targeting autoimmune diseases and transplantation, designed to selectively deplete pathogenic T cells.
- Utilizes protein engineering to optimize cytokine activity and create safe and effective treatments.